Background:
Recent studies have shown that hyperuricemia and gout, a condition with hyperuricemia associated with joint inflammation and/or renal manifestations, are associated with a higher risk of coronary artery disease (CAD), acute cardiovascular events including myocardial infarction (MI) and stroke, and cardiovascular mortality. Emerging data suggest that gout and hyperuricemia may also be associated with cardiac arrhythmias such as atrial fibrillation Objectives: To assess whether allopurinol use is associated with a reduction in the risk of ventricular arrhythmias (VA). Methods: We used the 5% random sample of Medicare beneficiaries from 2006-2012 to examine new allopurinol use and the risk of incident VA. Multivariable Cox regression analyses were adjusted for demographics (age, race, gender), comorbidity, cardiac medications and conditions associated with VA. We calculated hazard ratios (HR) and 95% confidence intervals (CI). Results: Of the 28,755 episodes of new allopurinol use, 2,538 were associated with incident VA (8.8%). Among patients with incident VA, 54% were male, 78% were White, and the mean Charlson-Romano comorbidity score was 4.8. The crude incidence of VA per 1,000,000 person-days declined as the duration of allopurinol use increased: 1-180 days, 151; 181 days-2 years, 105; and >2 years, 85. In multivariable-adjusted analyses, compared to non-use, allopurinol use was associated with lower HR of VA of 0.82 (95% CI, 0.76 to 0.90). Compared to allopurinol non-use, longer allopurinol use durations were significantly associated with lower multivariable-adjusted HR for VA: 1-180 days, 0.96 (95% CI, 0.85 to 1.08); 181 days to 2 years, 0.76 (95% CI, 0.68 to 0.85); and >2 years, 0.72 (95% CI, 0.60 to 0.87). Multiple sensitivity analyses adjusting for cardiac conditions, anti-arrhythmic drugs and alternate definitions confirmed our findings with minimal/no attenuation of estimates. Conclusions: Allopurinol use and use duration >6 months were independently associated with a lower risk of VA. Future studies need to assess the pathophysiology of this potential benefit. 
Recently an important role for synovial pathology in the initiation and progression of knee osteoarthritis (OA) has been emphasised. Our previous cross-sectional study showed that synovial changes on US associated with knee pain (KP), but the association was confounded by radiographic severity [1] Objectives: To examine whether these synovial changes associate with KP changes over 1 year. Methods: 220 participants with early KP (<3yrs duration) identified from the Knee Pain and Related Health in the Community (KPIC, n=9514) survey in Nottingham, UK formed the cohort for this study. All participants had bilateral US and radiographic examination at baseline, and US was repeated after 1 year. KP was defined as pain in or around the knee on most days for at least a month, and KP severity was measured using a numerical rating scale (NRS 0-10). Change in KP severity was defined according to a Patient Global Impression of Change. Synovial changes (effusion, hypertrophy and Power Doppler (PD) signal) were measured by two observers (inter-observer concordance correlation was 0.8 (0.6 to 0.9) for effusion and 0.7 (0.5 to 0.9) for synovial hypertrophy). Standardised radiographs (semi-flexed weight-bearing and flexed skyline views) were scored using the Nottingham Line Drawing Atlas (NLDA). Radiographic OA was defined as definite joint space narrowing (grade 2) plus definite osteophyte (grade 2) in any compartment. An absolute change in effusion/synovial thickness/pain scores was calculated by subtracting the baseline measure from the follow-up measure within individuals. A correlation analysis was used to examine the association between changes in pain and changes in US values. Potential baseline predictors for KP worsening were examined using multivariate logistic regression analysis. Results: Of 220 participants in this cohort, 165 (75%) had US measurements at baseline and follow-up (mean age 61yrs; 61% women; 24% ROA). The mean NRS score decreased from 4.44 to 3.01 mm. The mean depth of the effusion and synovial hypertrophy changed from 4.01 mm to 5.37 mm, and from 1.82 to 2.45 mm, respectively. There was no correlation between changes in pain on NRS and changes in US-detected synovial change (Figure 1) . At 1 year follow-up, 58% reported that their KP had improved from baseline, 16% reported worsening, and 27% reported no change in KP. After adjustment for age, gender and BMI baseline US features did not predict worsening pain, whereas ROA did (OR=4.06 95% CI 1.55 to 10.61).
Conclusions:
This cohort study showed that US-detected knee "synovitis" was not a predictor of change in OA symptoms, whereas baseline radiographic OA severity was. It suggests that synovial changes detected by US might reflect aspects of OA pathology discrete from mechanisms driving OA pain change.
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